Pharmaceuticals, Biotechnology and Life Sciences
– Conference call and webcast today at 4:30 p.m. ET – NEWARK, Calif.–(BUSINESS WIRE)–Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology…
Company announces initiation of MultiStem® Phase 2 study led by UTHealth in patients with trauma related inflammation and complications at…
– Patients reported significant pain reduction that was numerically greater than placebo, however, the primary efficacy endpoint was not met…
– U.S. Commercial Launch Preparations Underway Supporting the Tivozanib PDUFA Target Action Date of March 31, 2021 – – Ficlatuzumab…
SEATTLE–(BUSINESS WIRE)–Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for…
Reported positive topline data from pivotal Phase 3 Marigold Study of oral ganaxolone in children and young adults with CDKL5…
Investor conference call at 4:30 p.m. ET today SAN DIEGO–(BUSINESS WIRE)–$ARCT #Clinicaltrial–Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT),…
Interim Analysis of the pivotal 302 study (ALLELE) showed tab-cel® in EBV+ PTLD achieved a 50 percent objective response rate…
BEDFORD, Mass.–(BUSINESS WIRE)–$OCUL #OCUTX–Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies…
RADNOR, Pa.–(BUSINESS WIRE)–$MRNS #ChiefCommercialOfficer—Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat…